Tasuku Nakabori

17PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Clinical nutritionPredictive and prognostic markersAutoimmunityMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 14, 2026
Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer.

|Jun 12, 2026
Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

|Apr 09, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Yu Sato, Takahiro Kodama, Kazuki Maesaka

|Mar 10, 2026
Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study.

Ko Watsuji, Kenji Ikezawa, Yugo Kai

|Feb 11, 2026
Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.

Yugo Kai, Kenji Ikezawa, Kazuhiro Kozumi

|Jan 27, 2026
Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Tasuku Nakabori, Masaki Kawabata, Kaori Mukai

Pageof 3

Frequent Collaborators

7 joint publications

Kenji Ikezawa

6 joint publications

Ryoji Takada

3 joint publications

Takuo Yamai

3 joint publications

Makiko Urabe